A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Daiichi Sankyo
70 trials monitored
See 8 trials at risk
Heart Disease
8,814 trials monitored
See 428 trials at risk
Atrial Fibrillation
1,188 trials monitored
See 57 trials at risk
This study aims to evaluate the recommended once-daily dosing of edoxaban and rivaroxaban in patients with atrial fibrillation (AF) and renal dysfunction in South Korea and Taiwan. The findings will contribute to the growing body of evidence needed to guide clinical practice in managing AF patients with renal impairment in Asian populations.
Trial Details
NCT Number NCT07874555
Lead Sponsor Daiichi Sankyo
Conditions
(from sponsor)		 Atrial Fibrillation, Renal Dysfunction
Related terms Atrial Fibrillation, Renal Insufficiency
Enrollment 8,265 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov